AGM/EGMJun 1, 2026, 09:03 AM
Transcode Therapeutics Sets 2026 Annual Meeting for July 2
AI Summary
Transcode Therapeutics, Inc. announced its 2026 annual meeting of stockholders will be held on July 2, 2026, with May 28, 2026, set as the record date for voting. The company noted this date represents a change of more than 30 days from the one-year anniversary of its 2025 annual meeting, in compliance with Rule 14a-5(f) under the Exchange Act. Key deadlines for shareholder proposals and director nominations, including those under the universal proxy rules, are set for June 11, 2026.
Key Highlights
- Transcode Therapeutics will hold its 2026 Annual Meeting on July 2, 2026.
- The record date for stockholders entitled to vote is May 28, 2026.
- The 2026 Annual Meeting date is changed by over 30 days from the 2025 meeting anniversary.
- Shareholder proposals for proxy inclusion must be submitted by June 11, 2026.
- Stockholder nominations or business items must be submitted by June 11, 2026.
- Notices for universal proxy rule director nominees are due by June 11, 2026.
Price Impact
More from RNAZ